

Karina Dahl Steffensen
Professor, Overlæge, PhD
Onkologisk Afdeling/
Center for Fælles Beslutningstagning
Center Lillebælt
E-mail: karina.dahl.steffensen@rsyd.dk

Ansættelse

Professor

Institut for Regional Sundhedsforskning
SDU
21. dec. 2023 → 31. jan. 2028

Klinisk professor, Forskningsleder

Professor
IRS - Sygehus Lillebælt, Center for fælles beslutningstagning (Vejle)
SDU
21. dec. 2023 → 31. jan. 2028

Cheflæge - Center for Fælles Beslutningstagning

1. nov. 2014 → present

Overlæge - klinisk onkologi

Vejle Sygehus
Vejle, Danmark
1. okt. 2014 → 1. mar. 2022

Publikationer - peer reviewed

Through Clinicians Eyes: Use of an In-consultation Patient Decision Aid in Radiation Treatment for Early Breast Cancer: A Qualitative Study

Søndergaard, S. R., Stie, M., Bechmann, T., Offersen, B. V., Nielsen, M. H., Møller, M., Berry, L. L., Zachariae, R., Steffensen, K. D. & Lund, L., jun. 2024, I: *Clinical Breast Cancer*. 24, 4, s. e297-e309

Early integration of basic palliative care in cancer: Scoping review of cross-sectorial models - Components, facilitators, barriers

Swenne, J. I. E., Hansen, T. F., Nissen, R. D., Steffensen, K. D., Stie, M., Søndergaard, J. & Jensen, L. H., 25. apr. 2024, (E-pub ahead of print) I: *BMJ Supportive and Palliative Care*.

Shared decision making with breast cancer patients – does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial

Søndergaard, S. R., Bechmann, T., Maae, E., Mølby Nielsen, A. W., Nielsen, M. H., Møller, M., Timm, S., Lorenzen, E. L., Berry, L. L., Zachariae, R., Offersen, B. V. & Steffensen, K. D., apr. 2024, I: *Radiotherapy and Oncology*. 193, 9 s., 110115.

Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making: the IMPACTT randomised controlled trial protocol

Knudsen, B. M., Søndergaard, S. R., Stacey, D. & Steffensen, K. D., 12. mar. 2024, I: *BMC Cancer*. 24, 8 s., 336.

Communicating without a Shared Language: A Qualitative Study of Language Barriers in Language-Discordant Cancer Communication

Birkelund, L., Dieperink, K. B., Sodemann, M., Lindell, J. F., Steffensen, K. D. & Nielsen, D. S., 3. mar. 2024, I: *Journal of Health Communication*. 29, 3, s. 187-199

Decision aids for people facing health treatment or screening decisions

Stacey, D., Lewis, K. B., Smith, M., Carley, M., Volk, R., Douglas, E. E., Pacheco-Brousseau, L., Finderup, J., Gunderson, J., Barry, M. J., Bennett, C. L., Bravo, P., Steffensen, K., Gogovor, A., Graham, I. D., Kelly, S. E., Légaré, F., Sondergaard, H., Thomson, R. & Trenaman, L. & 1 flere, *Trevena*, L., 29. jan. 2024, I: *Cochrane Database of Systematic Reviews*. 2024, 1, 523 s., CD001431.

Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project

Rietjens, J. A. C., Griffioen, I., Sierra-Pérez, J., Sroczynski, G., Siebert, U., Buyx, A., Peric, B., Svane, I. M., Brands, J. B. P., Steffensen, K. D., Romero Piqueras, C., Hedayati, E., Karsten, M. M., Couespel, N., Akoglu, C., Pazo-Cid, R., Rayson, P., Lingsma, H. F., Schermer, M. H. N. & Steyerberg, E. W. & 3 flere, *Payne*, S. A., *Korfage*, I. J. & *Stiggelbout*, A. M., 2024, I: *Palliative Care and Social Practice*. 18

Development, implementation and evaluation of patient decision aids supporting shared decision making in women with recurrent ovarian cancer

Hæe, M., Wulff, C. N., Fokdal, L., Olling, K., Jensen, K. M., Hansen, D. G., Knudsen, A. Ø., Lemley, B., Blou, D., Büchmann, H. & Steffensen, K. D., dec. 2023, I: *PEC Innovation*. 2, 9 s., 100120.

Impact of an in-consult patient decision aid on treatment choices and outcomes of management for patients with an endoscopically resected malignant colorectal polyp: A study protocol for a non-randomised clinical phase II study

Würtz, H. J., Rahr, H. B., Lindebjerg, J., Edwards, A. & Steffensen, K. D., 14. nov. 2023, I: *BMJ Open*. 13, 11, 10 s., e073900.

Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer

Faaborg, L., Fredslund Andersen, R., Wen, S. W. C., Brenner Thomsen, C. E., Raunkilde, L., Hansen, T. F., Jensen, L. H., Dahl Steffensen, K. & Jakobsen, A., nov. 2023, I: *Future Oncology*. 19, 35, s. 2361-2367

Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer

Mortensen, C., Steffensen, K. D., Simonsen, E., Herskind, K., Madsen, J. S., Olsen, D. A., Iversen, D. B., Bergmann, T. K., Pottegård, A. & Stage, T. B., 1. jul. 2023, I: *Pain*. 164, 7, s. 1502-1511

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

You, B., Sehgal, V., Hosmane, B., Huang, X., Ansell, P. J., Dinh, M. H., Bell-McGuinn, K., Luo, X., Fleming, G. F., Friedlander, M., Bookman, M. A., Moore, K. N., Steffensen, K. D., Coleman, R. L. & Swisher, E. M., 1. jan. 2023, I: *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 41, 1, s. 107-116

"SDM:HOSP"- a generic model for hospital-based implementation of shared decision making

Steffensen, K. D., Hansen, D. G., Espersen, K., Lauth, S., Fosgrau, P., Pedersen, A. M., Groen, P. S., Sauvr, C. & Olling, K., jan. 2023, I: *PLOS ONE*. 18, 1, 20 s., e0280547.

Shared decision making in recurrent ovarian cancer: Implementation of patient decision aids across three departments of oncology in Denmark

Wulff, C. N., Hæe, M., Hansen, D. G., Olling, K., Jensen, K. M., Knudsen, A. Ø., Fokdal, L. & Steffensen, K. D., dec. 2022, I: *PEC Innovation*. 1, 10 s., 100095.

Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer

Carvalho, R. F., do Canto, L. M., Abildgaard, C., Aagaard, M. M., Tronhjem, M. S., Waldstrøm, M., Jensen, L. H., Steffensen, K. D. & Rogatto, S. R., dec. 2022, I: *Cell Communication and Signaling*. 20, 19 s., 176.

Decisional needs of patients with recurrent high-grade glioma and their families

von Essen, H. S., Stacey, D., Steffensen, K. D., Guldager, R., Poulsen, F. R. & Piil, K., okt. 2022, I: *Neuro-Oncology Practice*. 9, 5, s. 402-410

What can we learn from rapidly developed patient decision aids produced during the covid-19 pandemic?

Barry, M. J., Härter, M., Househ, M., Steffensen, K. D. & Stacey, D., 29. sep. 2022, I: *The BMJ*. 378, 5 s., e071530.

Development of a Patient Decision Aid to Support Shared Decision Making for Patients with Recurrent High-Grade Glioma

Sorensen von Essen, H., Poulsen, F. R., Dahlrot, R. H., Piil, K. & Steffensen, K. D., 1. jun. 2022, I: *International Journal of Environmental Research and Public Health*. 19, 12, 17 s., 7396.

Shared Decision Making with Acutely Hospitalized, Older Poly-Medicated Patients: A Mixed-Methods Study in an Emergency Department

Fabricius, P. K., Aharaz, A., Stefánsdóttir, N. T., Houliand, M. B., Steffensen, K. D., Andersen, O. & Kirk, J. W., 25. maj 2022, I: *International Journal of Environmental Research and Public Health*. 19, 11, 19 s., 6429.

The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms

Abildgaard, C., Do Canto, L. M., Rainho, C. A., Marchi, F. A., Calanca, N., Waldstrøm, M., Steffensen, K. D. & Rogatto, S. R., 1. apr. 2022, I: *Cancers*. 14, 7, 18 s., 1664.

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M. R., Brasiuniene, B., Madry, R., Brenton, J. D., Ausems, M. G. E. M., Büttner, R., Lambrechts, D., European experts' consensus group & Dahl Steffensen, K. (Medlem af forfattergruppering), mar. 2022, I: *Annals of Oncology*. 33, 3, s. 276-287

Patients' experiences of the decision-making process for clinical trial participation

A. Gregersen, T., Birkelund, R., Wolderslund, M., Dahl Steffensen, K. & Ammentorp, J., mar. 2022, I: *Nursing and Health Sciences*. 24, 1, s. 65-72

When life gives you no choice: Context of decision-making when offered an oncology clinical trial

Gregersen, T. A., Birkelund, R., Wolderslund, M., Steffensen, K. D. & Ammentorp, J., mar. 2022, I: *Scandinavian Journal of Caring Sciences*. 36, 1, s. 81-89

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study

Swisher, E. M., Aghajanian, C., O'Malley, D. M., Fleming, G. F., Kaufmann, S. H., Levine, D. A., Birrer, M. J., Moore, K. N., Spirtos, N. M., Shahin, M. S., Reid, T. J., Friedlander, M., Steffensen, K. D., Okamoto, A., Sehgal, V., Ansell, P. J., Dinh, M. H., Bookman, M. A. & Coleman, R. L., feb. 2022, I: *Gynecologic Oncology*. 164, 2, s. 245-253

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer: an ancillary data analysis of the VELIA trial

Aghajanian, C., Swisher, E. M., Okamoto, A., Steffensen, K. D., Bookman, M. A., Fleming, G. F., Friedlander, M., Moore, K. N., Tewari, K. S., O'Malley, D. M., Chan, J. K., Ratajczak, C., Hashiba, H., Wu, M., Dinh, M. H. & Coleman, R. L., feb. 2022, I: *Gynecologic Oncology*. 164, 2, s. 278-287

The challenge of involving old patients with polypharmacy in their medication during hospitalization in a medical emergency department: An ethnographic study

Fabricius, P. K., Andersen, O., Steffensen, K. D. & Kirk, J. W., dec. 2021, I: *PLOS ONE*. 16, 12, 20 s., e0261525.

Practitioners' views on shared decision-making implementation: A qualitative study

Ankolekar, A., Steffensen, K. D., Olling, K., Dekker, A., Wee, L., Roumen, C., Hasannejadasl, H. & Fijten, R., 11. nov. 2021, I: *PLOS ONE*. 16, 11, 18 s., e0259844.

Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement

Faaborg, L., Fredslund Andersen, R., Waldstrøm, M., Høgdall, E., Høgdall, C., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., nov. 2021, I: *Clinica Chimica Acta*. 522, s. 152-157

HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

Faaborg, L., Jakobsen, A., Waldstrøm, M., Petersen, C. B., Andersen, R. F. & Steffensen, K. D., okt. 2021, I: Biomarkers in Medicine. 15, 15, s. 1309-1317

Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards

Martin, R. W., Brogård Andersen, S., O'Brien, M. A., Bravo, P., Hoffmann, T., Olling, K., Shepherd, H. L., Dankl, K., Stacey, D. & Dahl Steffensen, K., okt. 2021, I: Medical Decision Making. 41, 7, s. 780-800

Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration

Witteaman, H. O., Maki, K. G., Vaissou, G., Funderup, J., Lewis, K. B., Dahl Steffensen, K., Beaudoin, C., Comeau, S. & Volk, R. J., okt. 2021, I: Medical Decision Making. 41, 7, s. 736-754

What Works in Implementing Patient Decision Aids in Routine Clinical Settings? A Rapid Realist Review and Update from the International Patient Decision Aid Standards Collaboration

Joseph-Williams, N., Abhyankar, P., Boland, L., Bravo, P., Brenner, A. T., Brodney, S., Coulter, A., Giguere, A., Hoffman, A., Körner, M., Langford, A., Légaré, F., Matlock, D., Mounjid, N., Munro, S., Dahl Steffensen, K., Stirling, C. & van der Weijden, T., okt. 2021, I: Medical Decision Making. 41, 7, s. 907-937

Association of patient-reported outcomes and ovarian cancer recurrence

Kargo, A. S., Jensen, P. T., Lindemann, K., Hjøllund, N. H., Liposits, G. I., Raaschou-Jensen, N., Knudsen, B. M., Möller, S., Hansen, D. G. & Steffensen, K. D., sep. 2021, I: International Journal of Gynecological Cancer. 31, 9, s. 1248-1259

ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows

Riis, C. L., Stie, M., Bechmann, T., Jensen, P. T., Coulter, A., Möller, S. & Steffensen, K. D., aug. 2021, I: Journal of Cancer Survivorship. 15, 4, s. 485-496

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

Aghajanian, C., Bookman, M. A., Fleming, G. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Jackson, C. G., Sullivan, D., Ratajczak, C. K. & Coleman, R. L., aug. 2021, I: Gynecologic Oncology. 162, 2, s. 375-381

The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study

Søndergaard, S. R., Madsen, P. H., Hilberg, O., Bechmann, T., Jakobsen, E., Jensen, K. M., Olling, K. & Steffensen, K. D., jul. 2021, I: Patient Education and Counseling. 104, 7, s. 1560-1567

Treosulfan in platinum-resistant ovarian cancer

Olesen, K. D., Larsen, A. T. R., Jensen, L. H., Steffensen, K. D. & Søndergaard, S. R., jul. 2021, I: International Journal of Gynecological Cancer. 31, 7, s. 1045-1051

Early ctDNA response to chemotherapy: A potential surrogate marker for overall survival

Jakobsen, A., Andersen, R. F., Hansen, T. F., Jensen, L. H., Faaborg, L., Steffensen, K. D., Thomsen, C. B. & Wen, S. W. C., maj 2021, I: European Journal of Cancer. 149, s. 128-133

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

Gultekin, M., Ak, S., Ayhan, A., Strojna, A., Pletnev, A., Fagotti, A., Perrone, A. M., Erzeneoglu, B. E., Temiz, B. E., Lemley, B., Soyak, B., Hughes, C., Cibula, D., Haidopoulos, D., Brennan, D., Cola, E., van der Steen-Banasik, E., Urkmez, E., Akilli, H. & Zapardiel, I. & 16 flere, Tóth, I., Sehoul, J., Zalewski, K., Bahremand, K., Chiva, L., Mirza, M. R., Papageorgiou, M., Zoltan, N., Adámková, P., Morice, P., Garrido-Mallach, S., Akgor, U., Theodoulidis, V., Arik, Z., Steffensen, K. D. & Fotopoulou, C., jan. 2021, I: Cancer Medicine. 10, 1, s. 208-219

The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness

Kargo, A. S., Jensen, P. T., Lindemann, K., Hjøllund, N. H. I., Lund, B., Hæe, M., Möller, S., Hansen, D. G. & Dahl Steffensen, K., 2021, I: Acta Oncologica. 60, 4, s. 434-443

Shared decision making in high-grade glioma patients-a systematic review

von Essen, H. S., Piil, K., Steffensen, K. D. & Poulsen, F. R., 1. dec. 2020, I: *Neuro-Oncology Practice*. 7, 6, s. 589-598

Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients

Hansen, M. K. G., Smerdel, M. P., Waldstrøm, M., Andersen, R. F., Adimi, P., Jakobsen, A. & Steffensen, K. D., dec. 2020, I: *Cancer Chemotherapy and Pharmacology*. 86, s. 751-759

Geographical distance as an impeding factor for cancer patients' participation in a specialised exercise programme

Hansen, A. M. E., Hansen, T. F., Steffensen, K. D. & Jensen, L. H., 30. nov. 2020, I: *Danish Medical Journal*. 67, 12, 8 s., A01200044.

Blood natural killer cells during treatment in recurrent ovarian cancer

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., nov. 2020, I: *Acta Oncologica*. 59, 11, s. 1365-1373

Cabazitaxel - A treatment option in recurrent platinum-resistant ovarian cancer

Vestergaard Madsen, C., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., sep. 2020, I: *Anticancer Research*. 40, 9, s. 5255-5261

Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol

Kargo, A. S., Coulter, A., Lindemann, K., Jensen, P. T., Hjøllund, N. H., Mosgaard, B. J. & Steffensen, K. D., sep. 2020, I: *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 30, 9, s. 1444-1449

Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma

Henriksen, J. R., Donskov, F., Waldstrøm, M., Jakobsen, A., Hjortkjaer, M., Petersen, C. B. & Dahl Steffensen, K., jun. 2020, I: *Acta Oncologica*. 59, 6, s. 652-659

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Steffensen, K. D., 15. maj 2020, I: *Journal of Ovarian Research*. 13, 9 s., 59.

Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial

Riis, C. L., Jensen, P. T., Bechmann, T., Möller, S., Coulter, A. & Steffensen, K. D., apr. 2020, I: *Acta Oncologica*. 59, 4, s. 444-452

Proposing a Bill of Rights for Patients With Cancer

Jacobson, J. O., Berry, L. L., Spears, P. A., Steffensen, K. D. & Attai, D. J., 1. mar. 2020, I: *Journal of Oncology Practice*. 16, 3, s. 121-123

Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer

Abildgaard, C., Canto, L. M. D., Dahl Steffensen, K. & Rogatto, S. R., 20. jan. 2020, I: *Frontiers in Oncology*. 9, 17 s., 1549.

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer

Rusan, M., Andersen, R. F., Jakobsen, A. & Steffensen, K. D., jan. 2020, I: *European Journal of Cancer*. 125, s. 121-129

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., Cloven, N. G., Oaknin, A., DiSilvestro, P. A., Morgan, M. A., Nam, J.-H., Leath, C. A., Nicum, S., Hagemann, A. R., Littell, R. D. & Cella, D. & 12 flere, Baron-Hay, S., Garcia-Donas, J., Mizuno, M., Bell-McGuinn, K., Sullivan, D. M., Bach, B. A., Bhattacharya, S., Ratajczak, C. K., Ansell, P. J., Dinh, M. H., Aghajanian, C. &

Bookman, M. A., 19. dec. 2019, I: The New England Journal of Medicine. 381, 25, s. 2403-2415

The impact of a patient decision aid on shared decision-making behaviour in oncology care and pulmonary medicine: A field study based on real-life observations

Olling, K., Stie, M., Winther, B. & Dahl Steffensen, K., dec. 2019, I: Journal of Evaluation in Clinical Practice. 25, 6, s. 1121-1130

A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid

Søndergaard, S. R., Madsen, P. H., Hilberg, O., Jensen, K. M., Olling, K. & Steffensen, K. D., nov. 2019, I: Patient Education and Counseling. 102, 11, s. 1961-1968

Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid

Andersen, S. B., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 4. okt. 2019, I: BMC Medical Informatics and Decision Making. 19, 9 s., 190.

Proactive use of PROMs in ovarian cancer survivors: a systematic review

Kargo, A. S., Coulter, A., Jensen, P. T. & Steffensen, K. D., 15. jul. 2019, I: Journal of Ovarian Research. 12, 8 s., 63.

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer

Hansen, T. F., Nederby, L., Zedan, A. H., Mejlholm, I., Henriksen, J. R., Dahl Steffensen, K., Thomsen, C. B., Raunkilde, L., Jensen, L. H. & Jakobsen, A., jul. 2019, I: Translational Oncology. 12, 7, s. 968-972

Development of a patient decision aid template for use in different clinical settings

Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Toftdahl, D. B., Hilberg, O., Coulter, A. & Dahl Steffensen, K., jun. 2019, I: European Journal for Person Centered Healthcare . 7, 1

What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences

Gregersen, T. A., Birkelund, R., Wolderslund, M., Netsey-Afedo, M. L., Steffensen, K. D. & Ammentorp, J., jun. 2019, I: Scandinavian Journal of Caring Sciences. 33, 2, s. 266-278

Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Van Calster, B., Stankusova, H., Delle Marchette, M., Mephon, A., Rouzier, R., Witteveen, P. O., Vergani, P., Van Calsteren, K., Rob, L. & Amant, F., 7. maj 2019, I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 29, 4, s. 676-682

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review

Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Steffensen, K. D., 27. mar. 2019, I: Patient Related Outcome Measures. 10, s. 117-127

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

Thomsen, C. B., Andersen, R. F., Steffensen, K. D., Adimi, P. & Jakobsen, A., mar. 2019, I: Pharmacological Research. 141, s. 392-396

Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation

Andersen, S. B., Birkelund, R., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 15. jan. 2019, I: Spine. 44, 2, s. 143-149

The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

Hjortkjær, M., Malik Aagaard Jørgensen, M., Waldstrøm, M., Ørnkov, D., Søgaard-Andersen, E., Jakobsen, A. & Dahl-Stefferen, K., jan. 2019, I: International Journal of Gynecological Cancer. 29, 1, s. 166-173

A design-led patient campaign development process for disseminating the concept of shared decision making
Akoglu, C., Dankl, K. & Dahl Steffensen, K., 2019, I: Design for Health. 3, 2, s. 305-323

Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy
Boucek, J., de Haan, J., Halaska, M. J., Plzak, J., Van Calsteren, K., de Groot, C. J. M., Dahl Steffensen, K., Fruscio, R., Massolt, E. T., Klaritsch, P., Zola, P., Amant, F. & International Network on Cancer, Infertility, and Pregnancy, jun. 2018, I: The Laryngoscope. 128, 6, s. 1493-1500

Behandling af primær og recidiverende ovariecancer
Rosendahl, M., Mosgaard, B. J. & Steffensen, K. D., 22. jan. 2018, I: Ugeskrift for Læger. 180, 4, s. 2-6 V03170213.

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status
Hjortkjær, M., Kanstrup, H., Jakobsen, A. & Dahl Steffensen, K., 1. jan. 2018, I: Cancer Treatment and Research Communications. 14, s. 7-12

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy
International Network on Cancer, Infertility and Pregnancy, 2018, I: Breast Cancer Research and Treatment. 168, 2, s. 551-557

Experiences of involvement in decision-making for patients with breast cancer: A phenomenological-hermeneutical study
Christoffersen, N., Olling, K., Dahl Steffensen, K. & Birkelund, R., 2018, I: European Journal for Person Centered Healthcare . 6, 2, s. 237-247

How participatory action research changed our view of the challenges of shared decision-making training
Ammentorp, J., Wolderslund, M., Timmermann, C., Larsen, H., Dahl Steffensen, K., Nielsen, A., Lau, M., Winther, B., Jensen, L. H., Assing Hvidt, E., Hvidt, N. C. & Gulbrandsen, P., 2018, I: Patient Education and Counseling. 101, 4, s. 639-646

Lessons in Integrating Shared Decision-Making Into Cancer Care
Steffensen, K. D., Vinter, M., Crüger, D., Dankl, K., Coulter, A., Stuart, B. & Berry, L. L., 2018, I: Journal of Oncology Practice. 14, 4, s. 229-235

Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., Halaska, M. J., Fruscio, R., Lok, C. A. R., Boere, I. A., Zola, P., Ottevanger, P. B., de Groot, C. J. M., Peccatori, F. A., Dahl Steffensen, K., Cardonick, E. H., Polushkina, E., Rob, L., Ceppi, L. & Sukhikh, G. T. & 3 flere, Han, S. N., Amant, F. & International Network on Cancer and Infertility Pregnancy (INCIP), 2018, I: Lancet Oncology. 19, 3, s. 337-346

Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study
Agergaard, K., Mau-Sørensen, M., Stage, T. B., Jørgensen, T. L., Hassel, R. E., Dahl Steffensen, K., Pedersen, J. W., Milo, M. L. H., Poulsen, S. H., Pottegård, A., Hallas, J., Brøsen, K. & Bergmann, T. K., sep. 2017, I: Clinical Pharmacology and Therapeutics. 102, 3, s. 547-553

Implementing shared decision making in Denmark: First steps and future focus areas
Dahl Steffensen, K., Hjelholt Baker, V. & Vinter, M. M., jun. 2017, I: Zeitschrift fuer Evidenz, Fortbildung und Qualitaet im Gesundheitswesen. 123-124, s. 36-40

Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma
de Haan, J., Lok, C. A., de Groot, C. J. M., Crijns, M. B., Van Calsteren, K., Dahl Steffensen, K., Halaska, M. J., Altintas, S., Boere, I. A., Fruscio, R., Kolawa, W., Witteveen, P. O., Amant, F. & International Network on Cancer, Infertility and Pregnancy (INCIP), jun. 2017, I: Melanoma Research. 27, 3, s. 218-223

Ovariecancer: tidlig opsporing i almen praksis og behandling

Jensen, P. T. & Dahl Steffensen, K., 2017, I: Best Practice Nordic.

The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection

Hjortkjær, M., Waldstrøm, M., Jakobsen, A., Kanstrup, H., Søgaard-Andersen, E. & Dahl Steffensen, K., 2017, I: International Journal of Gynecological Pathology. 36, 2, s. 180-189

Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

Steffensen, K. D., Adimi, P. & Jakobsen, A., 2017, I: International Journal of Gynecological Cancer. 27, 9, s. 1842-1849

The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Boisen, M. K., Madsen, C. V., Dehlendorff, C., Jakobsen, A., Johansen, J. S. & Dahl Steffensen, K., okt. 2016, I: International Journal of Gynecological Cancer. 26, 8, s. 1390-1398

Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue: A new paradigm in genetic counseling

Petersen, A. H., Jørgensen, M. M. A., Nielsen, H. R., Dahl Steffensen, K., Waldstrøm, M. & Bojesen, A., aug. 2016, I: European Journal of Human Genetics. 24, 8, s. 1104-1111

A case report of long term bevacizumab treatment in multiresistant ovarian cancer

Kargo, A. S., Adimi, P. & Dahl-Steffensen, K., 19. jun. 2016, I: International Journal of Cancer Therapy and Oncology. 4, 2, 4 s., 4214.

Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Lund, B., Sørensen, S. M., Petzold, M. & Jakobsen, A., 2016, I: Oncology Letters. 11, 6, s. 3967-3974

Cancer under graviditeten

Pedersen, B. W., Storgaard, L., Clausen, M. B., Kroman, N., Langhoff-Roos, J. & Steffensen, K. D., 29. jun. 2015, I: Ugeskrift for Læger. 177, 27, 5 s., V12140714.

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab

Steffensen, K. D., Madsen, C. V., Andersen, R. F., Waldstrøm, M., Adimi, P. & Jakobsen, A., okt. 2014, I: European Journal of Cancer. 50, 15, s. 2611-2618 8 s.

Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature

Verheecke, M., Halaska, M. J., Lok, C. A., Ottevanger, P. B., Fruscio, R., Dahl Steffensen, K., Kolawa, W., Gziri, M. M., Han, S. N., Van Calsteren, K., Van den Heuvel, F., De Vleeschouwer, S., Clement, P. M., Menten, J., Amant, F. & ESGO 'Cancer in Pregnancy' Task Force, maj 2014, I: European Journal of Cancer. 50, 8, s. 1462-1471 10 s.

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression

Steffensen, K. D., Smoter, M., Waldstrøm, M., Grala, B., Bodnar, L., Stec, R., Szczylik, C. & Jakobsen, A., maj 2014, I: International Journal of Oncology. 44, 5, s. 1736-1744 9 s.

Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting

Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., Han, S. N., Mir, O., Fruscio, R., Uzan, C., Maxwell, C., Dekrem, J., Strauven, G., Mhallem Gziri, M., Kesic, V., Berveiller, P., van den Heuvel, F., Ottevanger, P. B., Vergote, I. & Lishner, M. & 3 flere, Morice, P., Nulman, I. & ESGO 'Cancer in Pregnancy' Task Force, mar. 2014, I: International Journal of Gynecological Cancer. 24, 3, s. 394-403

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)

You, B., Colombaro, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. D., Reinthaller, A., Pujade-Lauraine, E. & Oza, A., aug. 2013, I: *Gynecologic Oncology*. 130, 2, s. 289-294

The need for more workshops in laparoscopic surgery and surgical anatomy for European gynaecological oncology trainees: a survey by the European Network of Young Gynaecological Oncologists

Manchanda, R., Halaska, M. J., Piek, J. M., Grabowski, J. P., Haidopoulos, D., Zapardiel, I., Gultekin, M., Vranes, B., Dallaku, K., Bossart, M., European Network of Young Gynecological Oncologists (ENYGO) & Dahl Steffensen, K., jul. 2013, I: *International Journal of Gynecological Cancer*. 23, 6, s. 1127-1132

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

Bechmann, T., Andersen, R. F., Pallisgaard, N., Madsen, J. S., Maae, E., Jakobsen, E. H., Bak Jylling, A. M., Steffensen, K. D. & Jakobsen, A., jun. 2013, I: *Journal of Cancer Research and Clinical Oncology*. 139, 6, s. 995-1003 9 s.

Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., apr. 2013, I: *Oncology Reports*. 29, 4, s. 1475-1482 8 s.

Cancer in pregnancy: a survey of current clinical practice

Han, S. N., Kesic, V. I., Van Calsteren, K., Petkovic, S., Amant, F., ESGO 'Cancer in Pregnancy' Task Force & Dahl Steffensen, K., 2013, I: *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 167, 1, s. 18-23

Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study

Steffensen, K. D., Waldstrøm, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2013, I: *International Journal of Gynecological Cancer*. 23, 1, s. 73-80

Predicting brain metastases of breast cancer based on serum S100B and serum HER2

Bechmann, T., Madsen, J. S., Brandslund, I., Lund, E. D., Ormstrup, T., Jakobsen, E. H., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., 2013, I: *Oncology Letters*. 6, 5, s. 1265-1270

Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2012, I: *Pathology Research International*. 2012, s. 851432 8 s.

Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Søgaard, C., Brandslund, I. & Jakobsen, A., 2012, I: *Clinical Ovarian and Other Gynecologic Cancer*. 5, 1, s. 10-16

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Steffensen, K. D., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, I: *Breast Cancer Research and Treatment*. 133, 1, s. 257-265

Prognostic Impact of VEGFA Germline Polymorphisms in Patients with HER2-positive Primary Breast Cancer

Maae, E., Fredslund Andersen, R., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, I: *Anticancer Research*. 32, 9, s. 3619-3627

Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Smerdel, M., Adimi, P., Brandslund, I. & Jakobsen, A., 2012, I: *Journal of Ovarian Research*. 5, 1, s. 23

Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors
Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Søgaard, C., Brandslund, I. & Jakobsen, A., 2012, I: *Anticancer Research*. 32, 9, s. 3817-3825

The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients
Steffensen, K. D., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012, I: *International Journal of Gynecological Cancer*. 22, 9, s. 1474-1482

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast
Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., aug. 2011, I: *Journal of Histochemistry and Cytochemistry*. 59, 8, s. 750-760

DNA-Repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival
Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, I: *Journal of Cancer Therapy*. 2, s. 140-147 7 s.

Gynecologic oncology training systems in europe: a report from the European network of young gynaecological oncologists
Gultekin, M., Dursun, P., Vranes, B., Laky, R., Bossart, M., Grabowski, J. P., Piek, J. M. J., Manchanda, R., Grimm, C., Dallaku, K., Babloyan, S., Moisei, A., Van Gorp, T., Cadron, I., Markov, P., Micevska, A., Halaska, M., Steffensen, K. D., Gristsenko, L. & Nissi, R. & 20 flere, Lambaudie, E., Tsitsishvili, Z., Haidopoulos, D., Tsolakidis, D., Novak, Z., Peiretti, M., Dunenova, G., Macuks, R., Hetland, T. E., Michelsen, T. M., Martins, F. C., Achimas-Cadariu, P., Ulrikh, E. A., Uharcsek, P., Malic, S., Ognjenovic, D., Zapardiel, I., Johann, S., Sukhin, V. S. & Manchanda, R., 2011, I: *International Journal of Gynecological Cancer*. 21, 8, s. 1500-6 7 s.

Improved classification of epithelial ovarian cancer: results of 3 danish cohorts
Steffensen, K. D., Waldstrøm, M., Grove, A., Lund, B., Pallisgård, N. & Jakobsen, A., 2011, I: *International Journal of Gynecological Cancer*. 21, 9, s. 1592-600 9 s.

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer
Steffensen, K. D., Alvero, A. B., Yang, Y., Waldstrøm, M., Hui, P., Holmberg, J. C., Silasi, D.-A., Jakobsen, A., Rutherford, T. & Mor, G., 2011, I: *Journal of Oncology*. 2011, s. 620523 12 s.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients
Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2011, I: *International Journal of Gynecological Cancer*. 21, 6, s. 1040-7 8 s.

The prognostic importance of EGFR and COX-2 expression in cervix cancer stages IIb-IVa
Adimi, P., Dahl Steffensen, K., Schledermann, D., Rasmussen, E. R. & Jakobsen, A., 2011, I: *Journal of Cancer Therapy*. 2, 1, s. 9-15

The prognostic value of Syndecan-1 in ovarian cancer patients with long-term follow-up
Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, I: *Clinical Ovarian Cancer*. 4, 1, s. 12-18

VEGF in the development of ovarian malignancy
Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Olsen, D. A., Brandslund, I. & Jakobsen, A., 2011, I: *Clinical Ovarian Cancer*. 4, 1, s. 19-25

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
Smerdel, M. P., Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 1. aug. 2010, I: *Gynecologic Oncology*. 118, 2, s. 167-71 5 s.

Supraclavicular recurrence after early breast cancer: a curable condition?
Pedersen, A. N., Møller, S., Steffensen, K. D., Haahr, V., Jensen, M., Kempel, M. M., Jepsen, S. L., Madsen, E. L., Roslind, A., Sandberg, E., Schöllkopf, C., Sørensen, P. G., Windfeldt, K. M. & Andersson, M., 8. maj 2010, I: *Breast Cancer Research and Treatment*. 125, 7, s. 815-822

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 5. jan. 2010, I: *Gynecologic Oncology*. 117, 1, s. 109-116

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Christensen, R. K., Bartels, A., Brünner, N. & Jakobsen, A., 1. jan. 2010, I: *BMC Cancer*. 10, s. 185

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M. & Jakobsen, A., 1. jul. 2009, I: *International Journal of Gynecological Cancer*. 19, 5, s. 820-5 5 s.

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer

Smerdel, M., Waldstrøm, M., Brandslund, I., Steffensen, K. D., Andersen, R. F. & Jakobsen, A., 1. maj 2009, I: *International Journal of Gynecological Cancer*. 19, 4, s. 578-84 6 s.

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Alvero, A. B., Chen, R., Fu, H.-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D.-A., Steffensen, K. D., Waldstrøm, M., Visintin, I. & Mor, G., 1. jan. 2009, I: *Cell Cycle*. 8, 1, s. 158-66 8 s.

Preoperative serum levels of epidermal growth factor receptor, HER2, and vascular endothelial growth factor in malignant and benign ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., dec. 2008, I: *Clinical Ovarian Cancer*. 1, 2, s. 127-134

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Olsen, D. A., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., 1. jul. 2008, I: *International Journal of Oncology*. 33, 1, s. 195-204 9 s.

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors

Steffensen, K. D., Waldstrøm, M., Olsen, D. A., Corydon, T., Lorentzen, K. A., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 1. jun. 2008, I: *Clinical Cancer Research*. 14, 11, s. 3278-3282 4 s.

Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

Chen, R., Alvero, A. B., Silasi, D.-A., Steffensen, K. D. & Mor, G., 7. jan. 2008, I: *Oncogene*. 27, 2, s. 225-233 8 s.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 24. okt. 2007, I: *International Journal of Gynecological Cancer*.

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007, I: *International Journal of Gynecological Cancer*. 17, 4, s. 798-807 9 s.

Publikationer - abstracts

Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2009, *Abstracts*. European Cancer Organization (ECCO)

Publikationer - posters

THE ROLE OF RELATIVES OF PROSTATE CANCER PATIENTS IN DECISION-MAKING CONVERSATIONS DURING HOSPITAL CONSULTATIONS – A QUALITATIVE STUDY

Lund, L., Knudsen, B. M., Schall Holberg, M., Nørby, B. & Dahl Steffensen, K., 7. jul. 2024. 1 s.

NAVIGATING A SHIFT: HEALTHCARE PROFESSIONALS' ATTITUDES TOWARDS LEARNING TO PRACTICE SHARED DECISION-MAKING

Rauff Søndergaard, S., Dahl Steffensen, K. & Lund, L., 1. maj 2024.

“STILLE MAND” - En fortælling om sygdom, sprogbarrierer og tændstikker

Birkelund, L., Dieperink, K. B., Sodemann, M., Lindell, J. F., Dahl Steffensen, K. & Nielsen, D. S., 30. okt. 2023.

Neurofilament light chain is a translational biomarker of paclitaxel-induced peripheral neuropathy

Mortensen, C., Dahl Steffensen, K., Simonsen, E., Herskind, K., Madsen, J. S., Aalund Olsen, D., Iversen, D. B., Bergmann, T. K., Pottegård, A. & Stage, T. B., 11. sep. 2022.

Shared decision making on radiation dose for stereotactic body radiotherapy of malignancies located less than 1 cm from the thoracic wall – A randomized trial

Fink, T. L., Kristiansen, C., Schjødt Hansen, T., Slot Thing, R., Hansen, T. F. & Dahl Steffensen, K., mar. 2022.

En antropologisk undersøgelse af implementering af fælles beslutningstagning i "Sammen om Valg – Et trygt forløb for den gynækologiske kræftpatient"

Mølgaard Jensen, K., Viggo Olesen, C., Hansen, D. G., Ør Knudsen, A., Fokdal, L., Wulff, C., Dahl Steffensen, K. & Olling, K., 2021.

National coverage of biological materials for translational research in the Danish cancerbiobank (RBGB) and of corresponding clinical data in the Danish Gynecological Cancer Database (DGCD): 645 - Poster Session

Høgdal, E., Schnack, T., Dahl Steffensen, K., Jochumsen, K., Kahr, H. S., Hjorth Ingerslev, K., Antonsen, S. L., Christensen, I. & Høgdal, C. K., mar. 2020.

Shared decision making at recurrent high-grade glioma (Fælles beslutningstagning ved recidiv af højgradsgliom.)

Sørensen Von Essen, H., Piil, K., Dahl Steffensen, K. & Rom Poulsen, F., 21. jan. 2020.

A study in optimizing follow up for postmenopausal women with breast cancer treated with adjuvant endocrine therapy

Lundgaard Riis, C., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 29. aug. 2019.

Blood natural killer cells as a new, independent prognostic factor in recurrent ovarian cancer

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. aug. 2019.

Fælles beslutningstagning for patienter med recidiv af højgradsgliom – hvordan gør vi og er det overhovedet relevant?

Sørensen Von Essen, H., Piil, K., Dahl Steffensen, K. & Rom Poulsen, F., 29. aug. 2019.

HOXA9 methylation as a prognostic marker in platinum-resistant ovarian cancer

Faaborg, L., Henriksen, J. R., Fredslund Andersen, R., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. aug. 2019.

Tissue immune response in ovarian cancer

Henriksen, J. R., Donskov, F., Jakobsen, A., Waldstrøm, M., Hjortkjær, M. & Dahl Steffensen, K., 1. jun. 2019.

Development of a decision aid to support ovarian cancer patient decide on CA125 biomarker monitoring

Kargo, A. S., Coulter, A., Jensen, P. T. & Dahl Steffensen, K., 12. apr. 2019.

Prognostic Impact of NK-cells, T-cells and PD-L1 in Ovarian Cancer

Henriksen, J. R., Waldstrøm, M., Donskov, F., Jakobsen, A., Hjortkjær, M. & Dahl Steffensen, K., 22. mar. 2019.

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? - A scoping review

Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 2019.

CABAZITAXEL - A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Madsen, C. V., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 16. sep. 2018.

SHARED DECISION MAKING IN THE CARE FOR THE GYNECOLOGIC CANCER PATIENT

Mette, H., Fokdal, L. U., Ør Knudsen, A., Madsen, C. V., Jensen, P. T., Lundvall, L., Olling, K., Lemley, B., Blou, D., Hanne, B. & Dahl Steffensen, K., 15. sep. 2018.

DEVELOPMENT OF A PATIENT DECISION AID TEMPLATE FOR USE IN DIFFERENT CLINICAL SETTINGS

Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Hilberg, O., Coulter, A. & Dahl Steffensen, K., 30. aug. 2018.

Kan anvendelse af Patient Reported Outcome Measures (PROM) forbedre opfølgningen af ovariecancer patienter? PROMova, et nationalt projekt.

Kargo, A. S., Coulter, A. (Medlem af forfattergruppering), Hjøllund, N. H. I. (Medlem af forfattergruppering), Jensen, P. T. (Medlem af forfattergruppering) & Dahl Steffensen, K. (Medlem af forfattergruppering), 30. aug. 2018.

Shared decision making in decision on adjuvant radiotherapy for early stage breast cancer patients

Bechmann, T., Ellegaard, M.-B. B., Hugger Jakobsen, E., Offersen, B. V., Bøje, C. R., Zachariae, B. & Dahl Steffensen, K., 30. aug. 2018.

Valg eller fravalg af CA125 blodprøver ved opfølgning af patienter med ovariecancer. Udvikling af et beslutningsstøtteværktøj

Kargo, A. S., Coulter, A. (Medlem af forfattergruppering), Jensen, P. T. (Medlem af forfattergruppering) & Dahl Steffensen, K. (Medlem af forfattergruppering), 30. aug. 2018.

Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.

Dahl Steffensen, K., Fredslund Andersen, R. & Jakobsen, A., 4. jun. 2018.

Optimeret opfølgning for brystkræftpatienter i sygehusregi

Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 18. jan. 2018.

Factors affecting patient decision-making on surgery for lumbar herniated disc

Brogård Andersen, S., Birkelund, R., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 2018.

Individual survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A. (Medlem af forfattergruppering), Hjøllund, N. H. I. (Medlem af forfattergruppering), Jensen, P. T. (Medlem af forfattergruppering) & Dahl Steffensen, K. (Medlem af forfattergruppering), 2018.

Validation and incorporation of oncologic and relapse data from Danish National Patient Registry (NPR) in the Danish Gynecological Cancer Database (DGCD)

Weng Ekman-Gade, A., Høgdall, C., Fagö-Olsen, C. L., Dahl Steffensen, K., Hjortkjær, M., Mejer Sørensen, S., Høgdall, E., Jochumsen, K., Antonsen, S. L., Ingerslev, K. H., Kahr, H. S. & Schnack Henriksen, T., 2018.

Is there a need for a Decision Aid in a Danish Spine Surgery Clinic or is Shared Decision Making already done?

Brogård Andersen, S., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 5. jul. 2017. 1 s.

Individuel survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A., Hjøllund, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 2017.

Neutrophils as a prognostic factor in the systemic treatment of Ovarian Cancer

Henriksen, J. R. & Dahl Steffensen, K., 29. okt. 2016.

LBA50 - Influence of concomitant clopidogrel consumption on development of paclitaxel-associated toxicity: A pharmacoepidemiological study

K, A., Mau-Sørensen, M., Stage, T. B., Dahl Steffensen, K., Hallas, J., Brøsen, K. & Bergmann, T. K., 8. okt. 2016.

A first step in shared decision making – developing a decision aid for the choice of anal cancer radiotherapy.

Olling, K., Wee, L., Jensen, L. H. & Dahl Steffensen, K., 19. sep. 2016.

Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study

Dahl Steffensen, K., Adimi, P. & Møller Jakobsen, A. K., 6. jun. 2016.

Forsøgs- eller standard behandling?

Gregersen, T. A., Ammentorp, J., Birkelund, R., Dahl Steffensen, K. & Wolderslund, M., 2016.

Prognosis of Patients with cervical cancer diagnosed during pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Skultety, J., Giuliani, D., Mephon, A., Rouzier, R., Witteveen, P. O., Locatelli, A., Rob, L. & Amant, F., 2014.

The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma – immunohistochemical detection

Hjortkjær, M., Waldstrøm, M., Kanstrup, H., Søgaard-Andersen, E., Jakobsen, A. & Dahl Steffensen, K., 2014.

The clinical outcome in breast cancer patients with HER2 status determined by a quantitative ELISA technique

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Olsen, D. A., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 5. maj 2012.

Quantitative tissue HER2 protein concentration does not expand the group of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 20. apr. 2012.

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., apr. 2012.

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast

Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., mar. 2012.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study

Dahl Steffensen, K., Waldstrøm, M., Pallisgaard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2012.

The prognostic and predictive value of combined HE4 and CA125 in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012.

The clinical significance of quantitative HER2 determination in breast cancer

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 10. mar. 2011.

Prognostic Impact of Prechemotherapy Human Epididymis Protein (HE4) and Cancer Antigen 125 (CA125) Levels in Ovarian Cancer Patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 6. mar. 2011.

Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.

You, B., Colombaro, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Fossati, R., Emons, G., Rehman, K. L., Petru, E., Gebiski, V., Burges, A., Tubiana-Matthieu, N., Hansen, M., Vasey, P. A., Denison, U., De Bruyne, P. & Oza, A. M., 2011.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, non-randomized, multicenter, phase II trial

Dahl Steffensen, K., Waldstrøm, M., Lund, B., Bergfeldt, K., Kjeldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2010.

Association of ERCC1 protein expression to platinum resistance in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2009.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D. & Jakobsen, A., 2009.

Absence of mutant epidermal growth factor receptor (EGFRVIII) in normal, benign, borderline and malignant ovarian tissue

Dahl Steffensen, K., Waldstrøm, M., Olsen, D. A., Corydon, T., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Multiplex serum tumor markers for the prediction of early relapse in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Brandslund, I. & Jakobsen, A., 2008.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Andersen, R., Olsen, D., Jeppesen, U., Knudsen, H., Brandslund, I. & Jakobsen, A., 2008.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D., Jakobsen, A. & Mor, G., 2008.

The prognostic importance of EGFR and COX-2 expression in advanced cervix cancer

Adimi, P., Schleder, D., Dahl Steffensen, K. & Jakobsen, A., 2008.

Comparison of immunohistochemistry and fluorescence in situ hybridization for the evaluation of Her-2 expression and prognostic value in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long-term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Kvalifikationer

PhD, PhD titel: "The HER Family in Epithelial Ovarian Cancer" - Biological and clinical aspects, Syddansk Universitet
2005 → 2008

Dimissionsdato: 18. sep. 2008

Cand Med, Aarhus Universitet

jan. 1992 → jan. 1999

Dimissionsdato: 22. jan. 1999

Aktiviteter

Gæsteophold i udlandet